Table 2.
Recent and current immunotherapy clinical trials for DMG.
| Intervention | Administration | Clinical Trial | Tumor Eligibility | Phase | Recruitment Status |
|---|---|---|---|---|---|
| C7R-GD2 CAR T cells | IV | NCT04099797 | Newly diagnosed; recurrent/refractory | I | Recruiting |
| GD2 CAR T cells | IV | NCT04196413 | Newly diagnosed | I | Recruiting |
| B7-H3 CAR T cells | Intratumoral; intraventricular | NCT04185038 | Newly diagnosed | I | Recruiting |
| Autologous dendritic cell vaccines (ADCV) | Intradermal | NCT02840123 | Newly diagnosed | I | Unknown |
| DNX-2401 | Intratumoral | NCT03178032 | Newly diagnosed | I | Active, not recruiting |
| DC vaccine/TMZ | IV | NCT03396575 | Newly diagnosed | I | Recruiting |
| cemiplimab (REGN2810) + RT | IV | NCT03690869 | Newly diagnosed; recurrent/refractory | I | Recruiting |
| H3K27M vaccine + nivolumab | IV | NCT02960230 | Newly diagnosed | I | Recruiting |
| Pembrolizumab | IV | NCT02359565 | Recurrent/refractory | I | Recruiting |
| APX005M [CD40 agonistic Ab] | IV | NCT03389802 | Newly diagnosed; recurrent/refractory | I | Recruiting |
| indoximod + RT/TMZ | PO | NCT04049669 | Newly diagnosed | II | Recruiting |
| IL12 adenovirus | Intratumoral | NCT03330197 | Newly diagnosed | I/II | Recruiting |
Abbreviations: IV (intravenous); PO (oral).